gsk responsible business supplement image hiv virus gsk responsible business supplement supplement commercially successful contents cover image operating responsibly statements lynn elsenhans chair gsks dolutegravirbased medicines provide muchneeded treatment improve peoples health corporate responsibility committee option people living hiv find emma walmsley chief executive officer create value shareholders supporting access dolutegravir society approach responsible business brazil botswana medicines patent pool report provides performance update benchmarks external perspective responsible business commitments across four independent commentary aron cramer key areas health behaviour people president ceo bsr planet overview information report supplemental highlights last months information gsks annual report health developing innovative products improving access healthcare patients consumers around world behaviour embedding values throughout business including ways research develop sell market products people creating inspiring supportive work environment encourages employees develop capabilities achieve best planet managing environmental impacts operations products across lifecycle reduce carbon emissions water use waste engage stakeholders examples engage key stakeholder groups data summary key data gsk responsible business supplement cr committee chairmans statement ceos statement global healthcare company expectation great honour leading gsk would like thank lynn stakeholders gsk deliver longterm value leadership chair corporate responsibility committee shareholders society indeed companies contribution oversees responsibility deliver longterm value society meeting societys challenges scrutinised never pleased introduce responsible business supplement challenge meet expectations therefore remains company important purpose help people strategic importance company chair corporate feel better live longer long history tackling responsibility committee together fellow committee worlds biggest health challenges know important members support board assessing company employees certainly important joined operating way seeks meet expectations company commitment improving global health extent embedded strategy made great later year responsible business continue leadership committee worked emma team challenge progress launch new investors patients consumers employees communities shape gsks responsible business agenda key focus commitments set year reviewing activity support companys new set focused long rightly expect companies consider social impact well financial impact seek create value long term five years ago longterm priorities innovation performance trust including term commitments since starting role taken opportunity understand global health environment health safety issues building trust demonstrate views broad range stakeholders feedback received among partners customers society critical sustainable played big part development new balanced set business enable gsk continue creating value delivering continuing commitment longterm priorities gsk innovation performance trust wider economic benefits society deliver societal value investing three deliver financial returns broader part role committee keep close eye evolving longterm societal contribution views companys key stakeholders committee held later year launch new set focused longterm discussion trends stakeholder expectations likely commitments demonstrate continuing commitment deliver influence trust performance gsk long term societal value biggest impact use scientific pleased take note investors increasingly looking technical knowhow address global health needs like hiv incorporate environmental social governance esg factors malaria need support sustainable access highquality alongside traditional financial analysis determining longterm products must also responsible business modern value company committee believes esg issues employer practices support talented people give best strong factor longterm company success fully supports independent benchmarking also important pleased direction travel year performance recognised improved role committee includes monitoring companys efforts position dow jones sustainability index achievement engage effectively key stakeholders welcome leading industry first access vaccines index enhanced content stakeholder engagement supplement antimicrobial resistance benchmark number one position also welcome external insight aron cramer first alltrials transparency index clinical trials reporting course president ceo bsr none would possible without hard work employees partners grateful efforts look forward working made great progress commitments set five beyond years ago document sets performance company well positioned transition new targets later support longterm strategic trust priority emma walmsley chief executive officer lynn elsenhans chair gsks corporate responsibility committee gsk responsible business supplement approach responsible business approach responsible business supports purpose help people feel better live longer progress looking forward focusing impact investors patients consumers employees communities responsible business supplement report progress given new longterm priorities work last five years expect companies consider social environmental well set commitments across four focus areas embed responsible business practices operations financial impact seek create value long term set five years ago direction set global goals later year launch new set commitments describing actions take help approach responsible business supports purpose help commitments complete ten progressing well one deliver societal value earn trust seek establish people feel better live longer focus researching track one work needed see much work clear ambitious targets drive impact progress three areas developing extending access medicines vaccines consumer deliver commitments embedded healthcare products improve peoples lives strive run everyday business practices operations addressing global health needs science business responsibly ethically invest people protect new longterm priorities creating sustainable access highquality products environment helping millions people around announced new company goal one worlds world supporting global goals health creating value responsible business modern employer practices innovative best performing trusted healthcare shareholders supporting longterm success business companies alongside goal also introduced three new long also continue seek transparent trusted engagement governance term priorities company innovation performance trust scientific medical communities address environmental impact responsible business activities overseen boardlevel maintain ethical standards conduct business corporate responsibility committee crc management key work areas covered report continue risks overseen audit risk committee even current commitment marked completed either innovation crc chaired nonexecutive director lynn elsenhans part business usual contribute directly one meets four times year discuss external issues could impact new targets operating principles means set business reputation provide strategic guidance review commitments covered report either reframed performance ceo chairman also attend meetings performance new target specifically focuses area integrated year much committees focus support new target phased activity reviewing companys proposals future responsible business completed andor longer priority publish activity support companys new longterm priority trust new set targets provide detailed analysis trust gsk responsible business supplement benchmarks external perspective reporting commentary aron cramer external benchmarking president ceo bsr gsk topped access medicine index since biennial assessment began would like commend gsk responsible also areas supplement could also led industry business supplement strengthened including first ever access vaccines index pleased see supplement begin clear wellconceived overall would welcome insight gsk collective well first anti microbial resistance statement purpose ceo emma walmsley lynn elsenhans challenges faced addressing issues supplement benchmark early chair boards cr committee letters make clear supplement correctly provides report gsks achievements companys essential purpose approach cr linked would hugely valuable also touch progress needs improved ranking third heartening see included review companys purpose made barriers present challenges second industry dow jones priorities wellreflected report specifically supplement speaks gsks commitment sustainability world europe indexes places us top respect gsks new trust priority company building healthcare infrastructure context sector economic environmental staked important territory commitment responsible challenges associated would valuable contribution social performance enterprise modern employer practices time public understanding crucial issue nature availability quality employment undergoing transformative insight approach sales adopted would change increasingly important dimension corporate also highly valuable given gsks leadership issue responsibility positive see called area focus gsk ranked third guardian additional analysis new approach working uk graduate employers made gsks strong performance commitments covered would contribution broader understanding issue top ten times top graduate supplement positive company looks ahead encourage employers section working third parties would enhanced gsk ambitious adopt new targets progress overview common issues identified requiring towards sustainable development goals depends large part follow action extensive reviews gsk conducts leadership private sector least time public sector leaders many parts world facing political challenges finally section engaging stakeholders would ftsegood index benchmarks strengthened information provides picture additional specific elements supplement merit positive attention companies based environmental stakeholders views perspectives gsks actions social governance esg practices gsks achievements transparency clinical trials strong point greatly appreciate opportunity review supplement gsk member since good see recognized third party assessments present independent view conveys companys similarly inclusion section approach tax tax objectives performance authorities extremely welcome companies include awarded grade important topic reports cdps climate change programme gsks performance diversity inclusion topic one global companies rightly received considerable attention strong recognised companies employee engagement figures appear demonstrate responding survey aron cramer business value efforts president ceo bsr achieved score cdps water programme second year running one companies achieve recognition gsk responsible business supplement overview year significant progress health bn developing treatments reducing child training health addressing cold tackling antimicrobial neglected tropical hiv mortality workers chain challenges resistance diseases received fda approval reached million achieved goal three new design synflorix trained end juluca first drug regimen children countries years early reach million vaccine means lasts days healthcare professionals donated nearly eight billion daily single pill treatment lifesaving interventions underserved people opening rather six hours responsible use antibiotics albendazole tablets prevent hiv potential make since beginning training means clinics pharmaceuticals pipeline lymphatic filariasis intestinal significant difference lives fiveyear partnership frontline health workers healthworkers able gepotidacin first new worms since people living hiv save children vaccinate children per vial class antibiotics read behaviour people planet transparent working employee inclusive workplace carbon emissions water use clinical trials third parties engagement ranked third party oversight engagement levels ranked st uk cut operational carbon using less water alltrials transparency index programme successfully increased significantly since stonewall workplace equality emissions since building longstanding rolled third last global employee survey index lists top total value chain emissions used water commitment transparency parties track employees proud work lgbt inclusive risen extend access clinical trials reach early gsk recommending employers uk medicines great place work working address read read read gsk responsible business supplement progress summary report covers progress set commitments set five years ago later publish new set commitments drive impact progress see health behaviour tackling biggest global health challenges promoting open innovation values patient focus transparency respect integrity underpin everything making medicines vaccines accessible strengthening healthcare systems commitment progress tracker commitment progress tracker innovation unmet medical needs completed ethical conduct progressing well better access medicines vaccines completed promoting values sales marketing practices completed building products better meet needs completed transparency clinical trial data completed strengthening healthcare infrastructure completed rigorous patient consumer safety progressing well reducing child mortality completed minimising animal testing completed fighting malaria completed respecting human rights progressing well eradicating polio progressing well working third parties progressing well access antiretroviral treatment hiv progressing well ensuring ethical interactions completed eliminating controlling neglected tropical diseases ntds progressing well people planet aim create safe healthy inclusive working environment everyone able working hard minimise environmental footprint every stage value inspired realise potential help us succeed chain extend access products people around world commitment progress tracker commitment progress tracker developing people healthy inspiring workplaces progressing well aiming carbon neutral work needed promoting inclusion diversity progressing well reducing water impact progressing well community volunteering create change completed reducing waste track completed commitment completed progressing well able demonstrate clear deliverables track work ongoing work needed work needed get commitment schedule gsk responsible business supplement health innovation unmet medical needs tackling antibiotic resistance alzheimers disease commitment adapt open innovation rd model extensive use misuse antibiotics means effectiveness participated collaborations accelerate development currently used diseases developing world ddw waned fast becoming major public health crisis without treatments alzheimers dementia including million apply areas great unmet medical need action million people could die drugresistant infections dementia discovery fund dementias platform uk accelerating every year scientific challenge including infectious disease medicines partnership continued work wellcome trusts alzheimers disease neuroimmunology consortium investigate whether mood disorders scale task remains significant important work pharmaceutical industry governments find creative ways alzheimers treated targeting immune system incentivise reward new research development antibiotics noncommunicable diseases africa vaccines play critical role avoiding need antibiotics completed support researchers projects across subsaharan africa preventing bacterial viral infections helped establish amr industry alliance coalition drive progress towards address increasing burden noncommunicable diseases ncds commitments made industry davos continent africa ncd open lab declaration industry roadmap amr progress initiated three new clinical research collaborations january ranked large pharmaceutical lab active collaborations aim improve companies access medicines foundations first amr diseases developing world understanding nature asthma cancer cardiovascular benchmark assesses pharmaceutical generics biotech open lab tres cantos spain offers external scientists access kidney disease african patients six projects form part company responses amr gsk received top scores three expertise resources discover innovative medicines ddws collaboration medical research councils south africa research areas rd manufacturing production appropriate tres cantos open lab foundation supported research access stewardship uk projects since opened seven new projects pharmaceuticals pipeline gepotidacin first new class results lab led publication papers also established collaboration open lab antibiotics expected progress phase iii clinical research peerreviewed scientific journals university witwatersrand south africa help build developed collaboration us government biostatistics capacity subsaharan africa partners biomedical advanced research development authority gsks ddw centre supported phase clinical trials new defense threat reduction agency candidate drug tuberculosis tb phase ii studies expected begin begun latestage preclinical studies promote responsible use antibiotics trained healthcare professionals globally management community molecule potential shorten treatment tb acquired respiratory tract infections appropriate usage antibiotics funding bill melinda gates foundation prescribing guidelines importance surveillance studies biopreparedness review antimicrobial resistance committed preparing global health threats maintain reserve capacity respond future influenza pandemics involved development universal influenza vaccine candidate number research partnerships continue advance rapidresponse vaccine platform technologies prepare future public health emergencies healthcare professionals trained globally vaccines unmet global health needs responsible use antibiotics gsk vaccines institute global health developing vaccines protect wide range diseases including shigella invasive nontyphoidal salmonella typhoid paratyphoid fever group streptococcus also participating publicprivate partnership develop vaccine hiv clinical trials underway clinical proof concept study new tb vaccine continues aeras nonprofit read online read online research biotech phase ii primary results available open innovation antibiotic resistance africa ncd open lab gsk responsible business supplement better access medicines vaccines also established contracts supply synflorix mdecins improving affordability developed countries commitment embed flexible pricing sans frontires msf unicef lowest prices support goal ensure working best interests strategy innovative business models immunisation programmes refugees patients shareholders prices new medicines prescription medicines vaccines increase usage vaccines reflect commitment establishing prices among less able access afford products supplied unicef million doses aim balance reward innovation access affordability rotarix protect rotavirus gastroenteritis including doses supported introduction pakistans vaccination programme us negotiate payers gain medicines favourable increased supply placement formularies list products covered health completed discussions gavi unicef determine meet insurers pharmacy benefit managers patients generally future demand lower outofpocket costs medicines preferred treatment formulary progress supported gavi pilots cervarix vaccine human papillomavirus hpv countries since gsk patient assistance program provided gsk prescribed gsk equitable pricing strategy medicines vaccines supplying cervarix first universal mass vaccination programme medicines vaccines patients valued based country disease area product type patients ability zimbabwe cervical cancer one leading causes million cost goods sold continue enhance pay also invest communities around world product deaths among women programme make easier patients use simplifying cash donations see global community investment gsk still company committed ten year price freeze digital platforms totalled million support countries transitioning gavi financing europe engage governments payers balance supporting affordability developing access affordability working towards sustainable health world intellectual property organization wipo middleincome countries systems support ongoing innovation international federation pharmaceutical manufacturers since capped prices patented medicines associations ifpma launched new partnership called least developed countries western europe patinformed facilitate access medicine patent information long manufacturing costs covered gsk played instrumental role development partnership vaccine doses go least developed low catalysed commitment make information middleincome countries lowest vaccine prices offered patent portfolio freely available organisations gavi vaccine alliance supports early announced plans restructure pharmaceutical countries gni per head less operations subsaharan africa improve oversight efficiency committed deliver million doses pneumococcal despite changes maintain commitment address vaccine synflorix gavi discounted price health challenges subsaharan africa patient access remains delivered million doses also expect make priority continue make medicines vaccines new synflorix fourdose vial presentation see available widely available across region gavisupported countries doses synflorix delivered gavi read online access healthcare gsk responsible business supplement building products better meet needs strengthening healthcare infrastructure reducing child mortality commitment continue build core range commitment continue work partners commitment continue invest innovative crosssector products formats better meet needs people support strengthening healthcare infrastructure partnerships reduce child mortality across globe including less able access anticipate could improve access healthcare afford products million underserved people vs completed completed completed progress progress progress successfully built new products meet medical needs since reinvested profits sales launched fiveyear partnership save children including new fourdose vial synflorix pharmaceutical consumer healthcare products least developed ambition help save one million childrens lives worlds countries ldcs million total strengthening local poorest countries need keep vaccines medicines refrigerated major healthcare infrastructure obstacle access hot countries received positive approach end first five years partnership scientific opinion european medicines agency ema partnerships amref health africa care reached million children countries new fourdose vial presentation synflorix pneumococcal international save children helped train lifesaving interventions together advocating universal vaccine designed specifically address cold chain challenges frontline health workers helping us exceed goal health coverage global national levels created reducing physical space required delivery storage reaching million underserved people new distributed potentially lifesaving medicine prevent umbilical cord programmes botswana cameroon namibia training infections chlorhexidine gel already benefited received prequalification assessment frontline health workers subsaharan africa beyond ldcs newborns gsk employees also raised million used un international procurement agencies support partnership distribution resourcelimited countries subject local zambia community health entrepreneurs trained regulatory approvals plan start supplying vaccine live well social enterprise established care next phase gsk save children partnership gavisupported countries international barclays reached approximately continue address child mortality launch people healthcare information entrepreneurs sold clinics healthcare workers able vaccinate nearly healthcare products alone children per vial compared existing synflorix twodose gsk products support livelihoods vial presentation new formulation allows vaccine last days opened instead six hours allowed extended mvaccination pilots vodafone nigeria existing format following request national ministry health tanzania support integrated sms reminders nearly vaccine doses administered children using new presentation synflorix platform also partnered vodafone others set vaccine helps address cold chain programme lesotho use mobile technologies help hivpositive children pregnant women access treatment challenges developing countries luc debruyne ilan godfrey save children president global vaccines read online read online read online giving mothers babies healthier start reinvesting healthcare save children partnership gsk responsible business supplement fighting malaria eradicating polio approved tafenoquine first new treatment p vivax commitment build year commitment commitment continue support objective malaria years potential become important contribute fight malaria continued eradicating polio providing vaccines unicef tool malaria elimination efforts support working rd investment partnerships ground achieved partnership medicines malaria venture bill melinda gates foundation path enable patient access need completed enable use tafenoquine treat p vivax malaria children progressing well completed first part study called teach assess appropriate dose using childfriendly dispersible formulation progress progress investing local programmes developing vaccines prevent malaria partnership comic relief supporting worldwide incidence polio declined since rtss vaccine malaria vaccine candidate date projects across four african countries greater mekong global polio eradication initiative launched years ago received positive scientific opinion european subregion south east asia focused fighting malaria despite enormous strides combating potentially debilitating medicines agency ema recommendation pilot improving health partnership aims help make sure lifethreatening disease still recorded cases implementation interventions prevent diagnose treat malaria get people final steps completely eradicate polio proving extremely need need projects range youthled following successful phase iii trials supporting plans challenging whos goal end polio met approaches increase malaria awareness training frontline pilot malaria vaccine implementation programmes subsaharan community healthcare workers volunteers across projects supported eradication efforts supplying africa working together path ministries tanzania ghana mozambique launched oral polio vaccine opv bivalent types health kenya ghana malawi stakeholders reached people monovalent types unicef ensure successful implementation pilot programmes parallel delivered million doses opv unicef gsk preparing implementation phase iv programme brings us billion doses delivered since starting manufacturing activities gsk donate first million doses rtss vaccine support pilot programmes subsaharan africa rtss vaccine aims protect children p falciparum malaria common subsaharan africa responsible malarial deaths worldwide clinical trials already underway doses oral polio vaccine nextgeneration vaccine well preclinical studies candidate delivered unicef molecules treat acute p falciparum malaria developing new treatments also late stage development tafenoquine single mia collis comic relief dose treatment p vivax malaria common south asia horn africa latin america results phase iii trials adults presented new drug application submitted us fda therapeutic goods administration australia seeking approval use prevention relapse read online read online fight malaria unicef information polio gsk responsible business supplement access antiretroviral treatment hiv eliminating controlling neglected tropical diseases accelerating access treatment commitment viiv healthcare continue innovative hiv drug dolutegravir made available research new treatments increase access medicines commitment help eliminate control ten neglected brazil first line treatment people living hiv care people living hiv around world never treatment well thirdline therapy patients tropical diseases ntds affect billion people support unaids deliver ambition previously treatment part national health including elimination lymphatic filariasis also work communities combat programme dolutegravir also available first line treatment lf continued investment rd ongoing stigma discrimination associated hiv botswana part national treat hiv programme product donations contribution london added essential medicines list russia declaration ntds following tentative fda approval first generic version dolutegravir introduced selected countries covered voluntary progressing well licence agreements unbacked medicines patent pool progressing well aurobindo pharma ltd licenses enable generic formulations progress dolutegravir including fixeddose combinations containing dolutegravir recommended dhhs us guidelines made progress received fda approval juluca first singletablet available generic manufacturers covering adults drug regimen dolutegravir rilpivirine maintenance children living hiv developing world gsk donated nearly eight billion albendazole tablets since virologically supressed hiv patients following positive phase iii including million reach million european commission fda approved reduction results also made regulatory submission european people lf intestinal worms april togo became first weight limit treatment hiv dolutegravir children medicines agency african country eliminate lf public health problem seven adolescents means yearolds eligible countries achieving later year estimates juluca marks important milestone hiv care providing new receive treatment number people risk lf infection requiring mass treatment option could make significant difference people positive action communities drug administration decreased billion people million living hiv reducing number antiretrovirals continue support hiv education prevention take receive lifelong treatment chronic condition viiv healthcares positive action programmes positive action research ntds continues two candidate molecules phase iii clinical trials begun two investigational awarded new grants across four main global programmes treatment visceral leishmaniasis discovered collaboration twodrug treatment regimens dolutegravir plus lamivudine men sex men transgender people girls dundee university progressing towards clinical studies cabotegravir plus rilpivirine longacting formulation women adolescents children also supported community organisations europe new grants two new positive also began programme phase iii studies evaluate action initiatives launched support women young people longacting injectable cabotegravir prevention hiv us infection highrisk populations resourcepoor settings part publicprivate collaboration positive action challenges work global partners find innovative solutions specific pressing issues affecting hiv epidemic postrape care girls received fda approval emergency settings antiretroviral adherence breastfeeding juluca important milestone hiv care mothers addressing stigma healthcare settings deborah waterhouse viiv healthcare global specialist hiv company majority owned gsk ceo viiv healthcare people living hiv know hiv status diagnosed receive sustained antiretroviral therapy receiving therapy undetectable viral load read online covers adults see mpp website viiv healthcare read online positive action programmes tackling ntds gsk responsible business supplement behaviour ethical conduct promoting values sales marketing practices people feel confident speak ran speak campaign commitment continue strengthen across business raise awareness multiple valuesbased culture training people commitment continue drive valuesbased approach channels offer people within outside gsk voice standards expected encouraging reporting concerns ask questions independent third party sales marketing practices across world concerns embedding values way confidentially anonymously preferred received interests consumers patients core measure employee performance reports available channels reviewed formal investigations initiated frequent categories reports employee performance completed progressing well product promotion instances past commercial practices progress brought regulatory sanctions company paid large progress fines past behaviours inconsistent expectations promoting valuesbased approach sales code conduct taken several actions improved training people gsk eliminated use individual sales targets controls aware need constant vigilance mandatory annual training values code conduct pharmaceutical vaccines sales representatives change designed help employees complementary workers uk serious fraud office continues investigate groups implemented us expanded markets understand put values practice daily working commercial operations number countries including china globally today sales representatives incentivised lives manage ethical dilemmas may encounter requested additional information group regarding third based selling competency broader business performance party advisers engaged company course china living values training emphasises zero tolerance approach valuesbased approach proving effective independent investigations us securities exchange commission bribery corruption highlights commitment issues assessment gsks respiratory vaccines salesforce showed department justice also investigating matters please product quality data protection provides overview key effectiveness continuing improve sales outcomes refer legal proceedings note companys risks employees complementary ranking within top quartile compared peers several annual report information workers completed training people also priority markets underwent additional training antibribery corruption help disciplinary action engaging healthcare professionals manage specific risks inherent roles responsibilities employees behave ways align policies introduced policy stop paying hcps speak take appropriate disciplinary action employees almost ethics compliance professionals gsk prescribers prescription medicines vaccines disciplined policy violations including certified skills ethics compliance academy believe policy improved transparency trust failing complete mandatory living values antibribery since launch feedback scientific experts important scientific dialogue corruption training within required timeframe gsk reduced intent continued assess well values embedded disciplined employees received documented warning policy transparent scientific dialogue engagement experts specific parts businesses around values maturity received verbal warnings interests working develop new medicines assessments conducted past two years individual areas dismissed agreed leave company voluntarily improve care patients business using insights assessments continue enhancing way values embedded ways working gsk discussion employees disciplined breakdown types policy violation address feedback consulted hcps guides facilitate conversations values business decided change policy allow fair market value training completion leaders teams widely used across business payments made gsk expert researchers hcps code conduct reporting investigating concerns attendancepayroll speak science behind products disease clinical practice limited number gsksponsored medicalled meetings want maintain open environment concerns raised good manufacturing practices good distribution practices marketing promotional activities read online ethical conduct local work regulations continued overleaf gsk policies codes standards policy violations gsk responsible business supplement promoting values sales marketing practices transparency clinical trial data continued approval signed datasharing agreement researchers commitment transparent possible believe change best interests patients access analyse data secure computer system clinical trial data including publishing clinical study helps effective transparent scientific dialogue allowing hcps end listed trials reports without patientlevel data outcome trials share new science primary focus remains wwwclinicalstudydatarequestcom also used internal medical experts speaking products medicines conducted gsk within appropriate sponsors since proposals approved related pay hcps talk products outside approved process making available researchers access gsk trial data result ten research papers medicalled scientific workshop symposium anonymised patient level data scientific enquiry published also continued efforts develop plain language summaries studies communicate results way continued strengthen online resources inhouse readily understandable people outside scientific community medical capabilities provide bespoke product information hcps using existing channels increased overall completed nine posted date gsk clinical study register interactions customers digital interactions growing progress disclosing payments made hcps committed disclosing payments make hcps ranked number one alltrials transparency activities advisory boards scientific symposiums index clinical trials transparency index published bmj market research help us develop medicines vaccines based first systematic assessment pharmaceutical meet patients needs fulfil requirements european companies including worlds largest companies published federation pharmaceutical industries associations efpia policies clinical trial registration reporting came first disclosure code disclosing payments named individuals assessment looked trial registration summary results disclosing aggregate basis payments related research clinical study reports individual patient level data builds development longstanding commitment clinical trial transparency gsk publishes payments made hcps markets across gsk one companies publishes clinical study europe including russia ukraine well australia japan reports reports form basis submissions regulatory us latest year reporting agencies end reports gsk longstanding commitment hcps consented disclose individualnamed transfers value result summaries trials publicly available clinical trial transparency countries possible local disclosure rules clinical study register also introduced new mobile application enable access register mobile devices efforts continue reflect europe consent contract policy means work hcps withhold consent gsk launched first trial sponsor data sharing platform patrick vallance publish payments received us reportable activities share access anonymised patientlevel data sharing access outgoing president rd data within six months publication interventional phase iiv clinical trials access data external researchers submit research proposal reviewed scientific merit independent review panel appointed wellcome trust read online read online sales marketing practices data transparency european federation pharmaceutical industries associations gsk study register gsk responsible business supplement rigorous patient consumer safety minimising animal testing addition continue support wider efforts enhance commitment continue ensure interests safety commitment rigorously challenge need animal detection monitoring understanding prevention side effects patients consumers paramount importance studies work minimise impact animal pharmaceutical products known pharmacovigilance way design undertake clinical trials welfare investing development alternative product quality assurance monitoring continued work partners studies sharing animalbased data develop infrastructure reporting side effects developing reporting adverse events ongoing product usage world extending access medicines vaccines transcelerate collaboration working others completed promote harmonised approaches procedures clinical progressing well development drugs implement key regulations reducing risks falsified medicines progress progress counterfeit products supported whos revised definitions substandard animal research essential discovery new medicines robust policies processes ensure safety patients falsified medicines clearly categorise two main required legally test safety medicines vaccines consumers clinical trial participants remained paramount types unsafe healthcare products pose important public committed applying rs approach replace reduce development testing manufacturing medicines vaccines health issue refine animal studies well demonstrating respect consumer healthcare products produced responsibility towards animals address distribution counterfeit products collaborate follow strict quality management system manufacturing customs authorities prevent import export availability following oneoff increase related integration comply regulations good manufacturing practice illicit products primary focus countries counterfeit novartis vaccines business maintained longstanding recent years proactively invested several quality products known manufactured known major downward trend number animals used used improvement programmes across sites terms facilities transit hubs illicit products approximately animals fewer previous year infrastructure ways working staff training awareness around rodents conducted training sessions customs officials key results increasingly borne fewer supply ports border crossings countries working together collaborated clinical experts regenerative medicine interruptions improving regulatory inspection record based aim help authorities identify seize shipments counterfeit university college london develop artificial human lung likeforlike comparison across business units products distributed markets around world enable study human respiratory pathology physiology regulatory inspections held manufacturing sites vitro also worked clinical oncologists bioengineers majority resulted zero minor observations queen mary university london develop tumour model committed addressing issues raised inspections part humanrelevant tool identification innovative cancer continual improvement programme regulatory authorities therapies systems reduce need animal studies accepted proposed plans corrective actions mimicking disease seen human organs tissues understanding risks past decade vaccines division working keep track risks quality safety standards reduce number animals needed quality control purposes global risk register performed audits efforts include innovative medicine initiatives vaccine trials conducted third parties behalf see data vaccine project collaborative initiative aims reduce animal summary also enhanced policy management testing required batch releases vaccines gsk human safety information gsk products trained activities led eu approval quality control test resulting relevant staff safeguard people take products reduction number rabbits needed testing take part clinical research read online read online pharmacovigilance use animals gsk responsible business supplement respecting human rights working third parties based initial risk assessment third parties commitment address un guiding principles commitment seek work third parties undergone extensive independent assessment ecovadis business human rights across operations share commitment high ethical standards covers management labour rights fair business practices supplier relationships operate responsible way performance gaps antibribery corruption environment sustainable procurement identified appropriate commit working monitoring risk compliance audits third party improve performance conducted third party audits health safety ethics environment labour rights also conducted third party audits focused specifically quality processes progressing well progressing well identify areas require improvement engage relevant third parties develop improvement plans track progress progress progress significant issues identified remain unresolved may choose suspend terminate work third party focus activities seven areas based operations spend billion every year suppliers distributors biggest potential affect human rights healthcare air quality organisations including vendors provide impact relating propellants clinical trial standards employment us wide range goods services continued practices patient safety product counterfeiting use thirdparty optimise increase spend preferred supplier base suppliers progress outlined relevant sections enable us build strong relationships suppliers report critical business included indepth information expectations overseeing third parties related human rights within mandatory annual living values gsk third parties include suppliers distributors training see particularly relation labour rights organisations transfer value third party supply chain also held workshop senior managers oversight programme strengthens management risk build awareness understanding labour rights risks gsks supply chain driving improvements third party network operations supply chains identify training ensure share values work ethical requirements teams across business business standards expected gsk end deployed rollout programme globally covering continued monitor existing suppliers screen new suppliers third parties expect remainder complete early third party oversight programme rolled globally see working third parties also standardised risk assessments third parties labour rights clauses contracts third parties updated conducted since inception programme supplier portal human rights policy information improvement plans agreed working labour rights support compliance third parties implement plans second annual modern slavery act statement published line uk legislation outlines policies processes minimise risk modern slavery within operations supply chain improvement plans agreed since inception read online third party oversight programme human rights statement read online modern slavery act statement ethical conduct third parties gsk responsible business supplement ensuring ethical interactions commitment demonstrate gsk interactions register lobbying costs relating gsk activities brussels approach tax us eu transparency register us federal patient advocacy groups political stakeholders lobbying register respectively cost representing substantial business employment conducted appropriately ethically transparently interest eu institutions million presence many countries around globe us spent million lobbying activities cost includes pay significant amount tax including operating advocacy offices brussels washington dc corporation business taxes well completed cost travel consulting industry bodies may also taxes associated employees lobby indirectly behalf publish list main trade association memberships website progress understand responsibility pay appropriate amount tax gsk make corporate political contributions however fully support efforts ensure companies appropriately transparent working patient advocacy groups federal election campaign act us employees financially tax affairs managed provide detail engaging supporting patient organisations gain support individual candidates political groups political approach tax published tax strategy annual report insights help us develop products advocate policies action committee pac employees pac contributed part approach align investment strategies better meet patient needs information support candidates went state candidates countries already substantial economic activity provide patient groups published website federal candidates government policies promote tax regimes attractive business investment transparent intent available hese latest available figures figures available april held patient advocacy leaders summits czech submission eus transparency register relevant tax payers uk patent box republic germany japan switzerland build relationships relationship tax authorities gsk employees patient advocates health policy experts seek maintain open positive relationships governments industry representatives tax authorities worldwide welcome constructive debate launched respiratory health advisory board made taxation policy representatives patient organisations provide perspectives international tax framework expert insights needs patients allow us support oecd g principle tax paid develop better medicines advocate policies based throughout supply chain profitmaking activities take place needs also supported second asia pacific patient lung transfer pricing summit connect patient leaders advocate lung health line oecd guidelines base transfer pricing policy communities improve understanding conditions armslength principle support transfer prices economic like asthma analysis reports tax havens engaging political stakeholders engage artificial tax arrangements without business expect everyone gsk follow guidelines code commercial substance seek avoid tax using tax havens conduct interactions stakeholders political transactions would fully disclose tax authority stakeholders exception rules apply public zerotolerance approach tax evasion facilitation tax evasion policy groups engage behalf comprehensive corporation tax criteria guide selection groups ensure share group paid corporate income tax million values million profits million million corresponding tax charge profits million million read online read online tax strategy patient group funding annual report public policy patient advocacy gsk responsible business supplement people developing people healthy employee engagement inspiring workplaces know listening responding protecting people commitment continue create working environment people critical success reportable injury illness rate per inspires people grow perform healthy hours worked compared rate comparable sustainable way leading companies sector remained low employees shared views several years global employee survey best response rate yet aligned survey questions new longterm business priorities innovation want prevent anyone getting hurt work help us performance trust progressing well better identify manage risks begun analysing results give us valuable insights people feel working happened worst case scenarios specific incidents gsk engagement levels increased significantly since last progress order improve effectiveness prevention measures survey employees recommending gsk great place work increase proud work gsk road safety remains one biggest risks tragically member developing talent sales force died result road traffic accident us employees felt particularly well ethical behaviour strengthened focus identifying key roles part efforts reduce risk continue focus training quality health safety wanted see us create better business monitoring top talent supporting development gsk drivers road safety opportunities development improve systems processes results survey discussed leaders employees also trained around people support promotion health wellbeing across business identify priority focus areas roles first second line leaders leaders shared committed providing health programmes services plan survey people twice year help us gauge progress knowledge helped improve colleagues performance help people make healthy choices assess health making coaching programmes employees stop smoking enough physical activity eat healthily focus new engagement programme lets talk aims get people used business skills training modules part suite energy matters ultimately want feel talking matters encourage share different training leadership programmes develop talent gsk healthier happier energised work home views ideas make gsk even stronger graduates postgraduates joined future leaders made programmes services leaders across business hosting conversations esprit development programmes gsk ranked third available top countries covering employees globally teams range topics feedback insights guardian uk graduate employers made top ten made access easier online hub also piloting sessions collated shared employees senior leaders help shape future plans organisation times top graduate employers personalised interactive digital health platform belgium helps welcomed apprentices uk canada ireland singapore employees assess health adopt healthier behaviours part us continue expand apprenticeship programmes virgin pulse global challenge gsk participants internationally uk gsk voted top employer took million steps result named active science school leavers entered top apprenticeship organisation second year running companies employers list first time also contributing partnership prevention pp programme offers development national apprenticeship standards chairing employees family members unprecedented access lifesciences trailblazer group preventive healthcare services immunisations cancer screening little extra cost extended programme investing people critical ensuring asia pacific region prepared extend europe pp available countries complete global longterm sustainability business rollout planned last five years employees claire thomas families accessed around health services senior vice president human resources programme read online based benchmarking data pharmaceutical safety group working gsk gsk responsible business supplement promoting inclusion diversity community volunteering create change women management commitment continue promote inclusion diversity commitment extend volunteering opportunities bring globally gsk svpvp positive change communities global health director providing individual development manager progressing well total completed progress global lgbt council continued engage people across gsk lgbt issues supported lgbt erg progress independent hampton alexander review ftse spectrum employee members across companies found gsk eighth highest proportion countries around world skillsbased volunteering give people opportunity women board line support communities global health build ftse average female representation among achieved full marks human rights campaign abilities experience executive committee members direct reports corporate equality index second consecutive year us also best best award inclusion volunteers countries took part flagship proportion women management roles gsk national business inclusion consortium lgbt chamber pulse volunteer partnership programme total provided globally provided coaching support highperforming commerce achieved rainbow tick certification new zealand million worth skilled services nonprofit partners female managers accelerating difference programme early ranked st uk stonewall workplace countries around started programme equality index lists top lgbt inclusive pulse individuals work nonprofit organisation promoted began compared employers uk three six months share expertise learn new skills women men across gsk period new singapore asia headquarters designed fully latest survey pulse programme volunteers women made new graduates esprit participants accessible people disabilities developed completing assignments agreed brought back new apprentices science technology inclusive design guide future buildings refurbishments new ideas fresh ways working gsk nonprofit partners engineering roles women traditionally also introduced service uk make easier also benefit agreeing volunteers either met underrepresented additionally womens leadership initiative employees request workplace adaptations flexible exceeded expectations employee resource group erg employee working assistive technology furniture access service everyone gsk also opportunity volunteer one day members countries rolled countries next years year support local communities orange days new uk legislation published data gender pay disability confidence network erg skillsbased volunteering opportunities october gap uk first time based comparison salaries employee members across countries support global people contributed hours global gender pay gap gsk permanent ukbased employees disability council driving change promoting disability month volunteering mean national average confidence throughout business also continue review pay equity global level young people learning disabilities developed currently seven nationalities represented board employment skills project search programme executive committee seventyeight nationalities represented operates us well uk orange future leaders graduate programme people senior programme employed people disabilities hours contributed people completed emerging leaders programme singapore age japan global month volunteering develop asia leadership pipeline read online inclusion diversity read online gender pay gap report employee volunteering gsk responsible business supplement planet aiming carbon neutral scope greenhouse gas emissions thousand tonnes coe indirect emissions commitment reduce overall carbon footprint scope emissions fell million tonnes coe vs carbon neutral value however baseline chain year result novartis integration increasing sales propellantbased inhalers engage suppliers drive improvement example encourage suppliers monitor work needed disclose performance ecodesk external resource offers benchmarking information helps develop improvement plans suppliers representing billion spend progress raw materials use ecodesk report environmental data overall value chain carbon footprint made scope also platform encourage suppliers emissions direct operations scope emissions share best practices sustainability gsk supplier exchange supplier base use products recognise outstanding performance annual supplier environmental sustainability awards awards went provide medicines vaccines consumer healthcare paharpur p small packaging supplier india efforts products people need around world target reduce water use model ag larger packaging supplier proving extremely challenging reduce overall value installation paper recycling facility site switzerland electricity steam propellant emissions chain footprint gas fuel manufacture inhalers latest analysis shows total value chain carbon footprint use products also significant impact scope sales force travel emissions emissions majority patient use propellantbased estimated million tonnes coe inhaler ventolin propellant greenhouse gas released reduction compared baseline value chain footprint increased use reducing impact propellant complex scope greenhouse gas emissions thousand tonnes co e continue research feasible solutions issue including operations changing way manufacture reducing amount operational emissions scope reduced propellant used maintaining efficacy safety patients compared previous year result continuing gsks new generation inhaler products using ellipta device focus energy efficiency measures purchasing renewable developed launched dry powder inhalers dpis energy since baseline reduced annual carbon release greenhouse gas emissions certified emissions energy use saving cumulative million assessment respiratory inhaler portfolio carbon trust tonnes coe showed lifecycle carbon footprint dpi around times lower propellantbased inhaler one months treatment global healthcare company ur recently available scope data contribute tackling one months treatment dose propellant inhaler carbon footprint effects causes climate change ao f c rbkg nc fo ooe tp p rie nr p oa f c k c ko gm cp oar e ed p w erit h p aa c k dose daily ellipta dpi roger connor president global manufacturing supply target purchased goods services u se products product logistics disposal products business travel air commuting emissions read online propellant emissions aiming carbon neutral use inhalers gsk responsible business supplement reducing water impact reducing waste commitment reduce water impact across value commitment reduce operational waste waste water pollution supply chain chain vs vs risk pharmaceuticals particularly antibiotics entering environment waste water pollution progressing well track growing concern active area research gsk part antimicrobial resistance amr industry alliance launched progress progress signatory industry roadmap progress combating amr continue seek ways use less water operations since cut operational waste producing robust controls manufacturing supply chain use products reduced less hazardous waste less nonhazardous waste working supply chain partners audit compliance water use since water use increased however progress towards target slowed share best practice managing environmental discharges driven growth vaccines business amount waste produced remained last year read amr efforts online therefore increased focus reclaiming waste example south africa cut water use beneficial use reuse recycling recovery examples months site cape town well running campaign include redistributing consumer products close expiry date encourage employees save water work home uk selling waste gelatine capsule production drought uk piloting campaign utility company paintball manufacturer poland encourage consumers turn tap brushing teeth around sites worldwide achieved zero waste water use water impact landfill tonnes operational waste amount water used across value chain one part ended landfill less waste sent landfill story measure overall water impact across four different recycled incinerated recover energy categories water scarcity local water quality health social risks regulatory reputational risks end pharmaceutical consumer healthcare manufacturing sites completed water risk assessments four categories line water stewardship standard sites process developing plans address risks sites worldwide achieved identified may include situations zero waste landfill working local communities stakeholders efforts enhance water stewardship prioritise sites areas water stress already addressing impacts waterstressed regions india value chain horlicks makes almost third entire value chain water footprint globally past five years assessed top ten milk malt wheat suppliers india understand water impacts implemented projects recharge water per year read online water stewardship policy read online reducing water impact reducing waste gsk responsible business supplement engage stakeholders welcome insights stakeholder relationships examples listen engage external stakeholders help us better understand listening people global employee survey responding feedback employees expectations identify societal see p listen respond people help us promoting dialogue asking ideas lets talk see p trends inform approach maintain strong employee engagement retain communicating regular updates purpose strategy progress live broadcasts talented people qa sessions messages ceo members corporate executive team responsible business phil thomson government multilateral president global affairs driving progress key global health priority areas world health assembly organisations joining coalition focused ending pneumonia deaths children five interact governments policymakers working uk government nhs establish future uk life sciences engaging stakeholders played following clear transparent standards advocate sector post brexit policies encourage innovation promote partnering key stakeholders develop vaccine procurement mechanisms humanitarian key part development new efficient management healthcare spending settings see p longterm priorities innovation performance give patients support need trust provide examples engage key stakeholder groups investors links information specific communicate strategy responsible running investor roadshows conferences events see gskcom engagement outcomes business approach performance investor holding onetoone meetings individual investors including sris community including socially responsible investors responding investor surveys dow jones sustainability index djsi see p sris various channels partnering nonprofits implement programmes strengthen healthcare infrastructure see p ngos local communities supporting people living hiv viiv healthcares positive action programmes see p work partners strengthen working malaria comic relief advocate uk government healthcare infrastructure improve malaria summit commonwealth heads government meeting access healthcare global working save children combining expertise resources influence reduce local community programmes child mortality see p patient groups healthcare running patient advocacy leaders summits see p professionals setting advisory boards representatives patient organisations see p providing financial support patient groups disclosed website engage support patient organisations gain insights enable us develop products online resources inhouse medical capabilities provide information medicines advocate policies better meet patient needs vaccines healthcare professionals want see p communicating values expectations responsible business supplier portal suppliers third parties sharing best practices supporting improvements environmental performance aim build strong relationships supplier exchange suppliers third parties engaging suppliers social environmental performance third party share values oversight programme external platforms ecovadis ecodesk see p gsk responsible business supplement data summary health better access number doses synflorix vaccine supplied gavi million medicines vaccines number doses rotarix vaccine supplied gavi million value gsk medicine vaccines prescribed us patient assistance programme cost goods sold million usd number patients reached us patient assistance programme community investment cash million product inkind million time million management costs million strengthening healthcare health worker training programmes million infrastructure health workers partners trained cumulative number people reached reinvestment programme million cumulative neglected tropical diseases albendazole tablets help lymphatic filariasis lf elimination million albendazole tablets help treat intestinal worms million eradicating polio number doses oral polio vaccine delivered global polio eradication initiative million behaviour compliance employees disciplined policy violations employees dismissed agreed leave company voluntarily documented warnings total number marketing promotional activity violations number contacts made speak channels clinical trial data publicly available trial result summaries cumulative number studies clinical study reports posted register number trials listed patient level data available request number research teams approved access gsk trial data figures include healthworker programmes beyond least developed country ldc programmes figure includes projects related novartis assets projects fully transitioned novartis figure excludes projects related novartis projects gsk responsible business supplement behaviour clinical research audits investigator sites audits gsk processes audits gsk local operating companies investigations suspected irregularities audits contract research organisations total audits undertaken anticounterfeiting number trainings customs officials ensuring quality manufacturing number regulatory inspections pharmaceutical business supply number regulatory inspections vaccines business number regulatory inspections consumer healthcare business people health safety number fatalities reportable incidents lost time lost time reportable injury illness rate reportable incidents without lost time reportable injury illness rate talent leadership development total number coaching assignments number graduates recruited future leaders programme number postgraduates recruited esprit programme number apprentices recruited inclusion diversity percentage women management total volunteering number employees completing pulse health safety data restated include former novartis sites acquired gsk responsible business supplement planet carbon scope ghg emissions tonnes coe gas fuel electricity steam propellant emissions manufacture inhalers sales force travel emissions total scope ghg emissions tonnes coe purchased goods services product logistics business travel air commuting propellant emissions use inhalers use products disposal products emissions total water water use operations million cubic metres waste total waste generated thousand tonnes waste landfill thousand tonnes compliance internal audits number environmental fines environmental remediation spend million propellant emissions data collected internal systems accurate picture scope ghg emissions later year detailed breakdown environmental fines available responsible business supplement fines mostly due discovery waste tank upper merrion site comply local regulations plus fine paid hamilton site failure submit risk management plan storage use chloroform take responsibility removing pollution contaminants soil surface ground water facilities used previously disposal sites waste management companies used gsk responsible business supplement reporting report performance annually report part commitment open transparent business activities responsible business also covered annual report data coverage feedback counts data report relates gsks global operations welcome feedback responsible business calendar year except otherwise stated data performance reporting also request receive contributing global goals environment health safety sections independently regular updates progress verified dnv gl brand names appearing italics throughout summary assurance statement gsk opportunity make significant contribution report trade marks either owned licensed gsk independent assurance provider dnv gl provided un sustainable development goals sdgs associated companies limited assurance accordance assurance standard fully committed using expertise experience reporting standards isae revised assurance scope included selected support latest materiality assessment index global reporting initiative guidelines shows ehs performance data disclosed pages used sdgs key input elements covered report signatory responsible business supplement leading global healthcare business make un global compact publish annual communication dnv gls full statement including assurance conclusion biggest difference sdg ensure healthy lives progress demonstrate uphold ten principles summary work performed found website promote wellbeing particular key target within available gskcom please contact us csrcontactgskcom sdg achieving universal health coverage portfolio policies codes standards alongside commitments access innovation flexible number policies codes standards accessible pricing clearly support target website covering range different areas public health business integrity environment found also aim contribute several sdgs downloaded including gender equality good jobs economic growth environmental challenges read online public policy sdgs sdg factsheet